Cardiovascular risk assessments in chronic myeloid leukemia allow identification of patients at high risk of cardiovascular events during treatment with nilotinib

American Journal of Hematology

Volumn 90, Issue 5, 2015, Pages E100-E101

  Breccia, Massimo ^a   Colafigli, Gioia ^a   Molica, Matteo ^a   Alimena, Giuliana ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

DASATINIB; IMATINIB; NILOTINIB; 4-METHYL-N-(3-(4-METHYLIMIDAZOL-1-YL)-5-(TRIFLUOROMETHYL)PHENYL)-3-((4-PYRIDIN-3-YLPYRIMIDIN-2-YL)AMINO)BENZAMIDE; ANTINEOPLASTIC AGENT; PYRIMIDINE DERIVATIVE;

CANCER CHEMOTHERAPY; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CHRONIC MYELOID LEUKEMIA; FRAMINGHAM RISK SCORE; HEART INFARCTION; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; LETTER; OBESITY; PATIENT IDENTIFICATION; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PRIORITY JOURNAL; QRISK SCORE; RISK ASSESSMENT; UNSTABLE ANGINA PECTORIS; ADULT; AGED; CARDIOVASCULAR DISEASES; COMPLICATION; FEMALE; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MALE; MIDDLE AGED; PATHOLOGY; PATIENT SELECTION; RETROSPECTIVE STUDY; RISK FACTOR; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; CARDIOVASCULAR DISEASES; FEMALE; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MALE; MIDDLE AGED; PATIENT SELECTION; PYRIMIDINES; RETROSPECTIVE STUDIES; RISK FACTORS;

EID: 84928248256     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.23976     Document Type: Letter

References (9)

1. Hughes T, White D. Which TKI? An embarassment of riches for chronic myeloid leukemia patients. Hematology Am Soc Hematol Educ Program 2013;2013:168-175.
2. Valent P, Hadzijusufovic E, Schernthaner G-H, et al. Vascular safety issues in CML patients treated with BCR/ABL1 kinase inhibitors. Blood 2015;125:901-906.
3. Larson RA, Kim D-W, Issaragrilsil S, et al. Efficacy and safety of nilotinib vs imatinib in patients with newly diagnosed chronic myeloid leukemia in chronic phase: Long-term follow-up of ENESTnd. Blood 2014;124:4541.
4. Breccia M, Molica M, Zacheo I, et al. Application of systematic coronary risk evaluation chart to identify chronic myeloid leukemia patients at risk of cardiovascular diseases during nilotinib treatment. Ann Hematol 2015;94:393-397.
5. Rea D, Mirault T, Raffoux E, et al. Uselfuness of the 2012 european CVD risk assesment model to identify patients at high risk of cardiovascular events during nilotinib therapy in chronic myeloid leukemia. Leukemia 2014 Dec 8. doi: 10.1038/leu.2014.342.
6. Perk J, De Backer G, Gohlke H, et al. European guidelines on cardiovascular disease prevention in clinical practice (version 2012): The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by Representatives of Nine Societies and by Invited Experts). Int J Behav Med 2012;19:403-488.
7. Wilson PW, D'Agostino RB, Levy D, et al. Prediction of coronary heart disease using risk factor categories. Circulation 1998;97:1837-1847.
8. Hippisley-Cox J, Coupl C, Vinogradova Y, et al. Predicting cardiovascular risk in England and Wales: Prospective derivation and validation of Qrisk2. BMJ 2008;336:1475-1482.
9. Breccia M, Alimena G. Firstline treatment for chronic phase chronic myeloid leukemia patients should be based on a holistic approach. Expert Rev Hematol 2014;28:1-3.